ClinicalTrials.gg
CompletedNCT01930708PROTECUpdated Mar 19, 2020

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

A Phase 4 interventional study of dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis, sponsored by Biogen. Completed at 90 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-19.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,114
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
4th of 22
1,114 · median 61
Started
2013
with 1 other
Phase 4
9 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 4, and was the 7th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period.

The secondary objectives of this study in this population are to assess the impact of DMF over a 12-month period on participants -reported health-related quality of life (HRQoL) outcomes, additional clinical effectiveness outcomes, and health economics-related outcomes, and to characterize participants-reported adherence to DMF.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis

Keywords

  • BG-12
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and satisfy the approved therapeutic indication for DMF (per the local DMF product information).
  • Must be naïve to DMF, Fumaderm®, and other compounded fumarates, and to MS therapies that are primarily prescribed (e.g., natalizumab, fingolimod) and to alemtuzumab.
  • Have a recent complete blood count (CBC) that does not preclude the subject's participation in the study, in the judgment of the Investigator.

Key Exclusion Criteria:

  • Are unwilling or unable to comply with study requirements, or are deemed unsuitable for study participation as determined by the Investigator.
  • Have major comorbid conditions that preclude participation in the study, as determined by the Investigator.
  • Are pregnant, unless DMF is clearly needed and the potential benefit of DMF to the subjects justifies the potential risk to the fetus, in the judgment of the Investigator (in all countries except Austria). In Austria, pregnant subjects are excluded from participation in the study.
  • Are women of and are not using appropriate (per the local DMF product information) as determined by the Investigator.
  • Women who are breastfeeding may be excluded (per the local DMF product information) at the discretion of the Investigator.
  • Have previously received or are receiving treatment with MS therapies primarily used second-line (e.g., natalizumab, fingolimod) or alemtuzumab, or are currently receiving and planning to continue on other disease-modifying therapies for RRMS.
  • Are hypersensitive to the active ingredient in the DMF drug product (i.e., DMF) or to any of the listed in the local DMF product information.
  • Current enrollment in any clinical trial except for the Biogen Idec DMF Pregnancy Exposure Registry or other studies that, according to the study Medical Director, do not conflict with this study (e.g., health economics studies or local registries).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,114 participants (actual)

Study arms

  • Experimental
    DMF

    120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.

    Drug: dimethyl fumarate

Interventions

  • Administered as per the approved dosage in all countries where DMF has received marketing authorization.

    Also known as: Tecfidera, DMF, BG00012

06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate (ARR)

    Time frame: 12 Months

Secondary outcomes

  1. Change from Baseline in Multiple Sclerosis Impact Scale (MSIS-29) score

    This is a validated, 29-item, MS-specific HRQoL scale that measures the physical (20 items) and psychological (9 items) impact of MS on the participant's day-to-day life during the previous 2 weeks. For each item, the subject is asked to circle the number that best describes his or her situation. The numbers for each item range from 1 (not at all) to 5 (extremely).

    Time frame: 12 Months

  2. Change from Baseline in Modified Fatigue Impact Scale-5 Item (MFIS-5) score

    This scale consists of 5 statements that describe how fatigue may affect a person. For each statement, the participant is asked to circle the number that best indicates how often fatigue has affected him or her during the previous 4 weeks. The numbers for each question range from 0 (never) to 4 (almost always).

    Time frame: 12 Months

  3. Change from Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) score

    This is a validated, 14-item questionnaire that measures a participant's level of satisfaction/dissatisfaction with medication.

    Time frame: 12 Months

  4. Change from Baseline in EQ-5D 5 level version (EQ-5D-5L) index

    The widely validated EQ-5D includes 2 components, the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the subject is instructed to indicate whether he or she has "no problems" (level 1), "slight problems" (level 2), "moderate problems" (level 3), "severe problems (level 4), or "extreme problems/inability" (level 5) on that day. For the EQ VAS, the participant is instructed to mark an "x" on a vertical scale at the point that best describes his or her own health on that day, where 0 represents the "worst health" he or she can imagine and 100 the "best health" he or she can imagine.

    Time frame: 12 Months

  5. Change from Baseline in participants-Reported Indices for Multiple Sclerosis-Activity Limitations (PRIMUS-Activity Limitations) score

    This 15-item component of the PRIMUS assesses a participant's ability to carry out various activities of daily living during the previous week without the use of aids (e.g., cane, walker, or wheelchair) or assistance. For each item, the participant is asked whether he or she can perform the activity without difficulty or with difficulty, or is unable to perform the activity.

    Time frame: 12 Months

  6. Change from Baseline in Work Productivity and Activity Impairment-Multiple Sclerosis version (WPAI-MS) score

    This 6-item instrument assesses employment status, and, during the previous 7 days, hours of missed work due to MS or other reasons, hours worked (if employed), effect on productivity due to MS while working, and activity impairment attributable to health problems.

    Time frame: 12 Months

  7. Change from Baseline in Beck Depression Inventory-Fast Screen (BDI-Fast Screen) score

    This is a 7-item scale that evaluates depression in participants with medical illness during the prior 2 weeks. It has been validated in subjects with MS.

    Time frame: 12 Months

  8. Proportion of participants with confirmed (24-week) Expanded Disability Status Scale (EDSS) progression

    The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.

    Time frame: 12 Months

  9. Annualized Relapse Rate (ARR) at Baseline (i.e., over the 12 months prior to enrollment) and at Month 6

    Time frame: Baseline, 6 Months

  10. The proportion of participants relapsed

    Time frame: 12 Months

  11. Number of participants who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS

    Time frame: 12 Months

  12. Proportion of participants who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS

    Time frame: 12 Months

  13. Proportion of participants who report taking the prescribed DMF dose

    Time frame: 12 Months

  14. Percentage of participants who report taking the prescribed DMF dose

    Time frame: 12 Months

  15. Reasons reported by participants for not taking prescribed DMF dose

    Time frame: 12 Months

  16. Change from baseline in EQ Visual Analog Scale (EQVAS) score

    A component of the EQ-5D, where participants are asked to rate their overall health-related quality of life on a standard vertical 20 cm visual analogue scale (similar to a thermometer) between 100 (best health imaginable) and 0 (worst health imaginable).

    Time frame: 12 Months

07

Study locations

90 sites
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Klagenfurt, 9026, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    St. Polten, 3100, Austria
  • Research Site
    Villach, 9500, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, 1220, Austria
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Melsbroek, 1820, Belgium
  • Research Site
    Calgary, Alberta T2N 2T9, Canada
  • Research Site
    Victoria, British Columbia V8R 1J6, Canada
  • Research Site
    St. John's, New Brunswick E2K 5S9, Canada
  • Research Site
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Montreal, Quebec H8A 2B4, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Havirov, 736 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Pardubice, 532 03, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Strasbourg Cedex, Bas Rhin 67098, France
  • Research Site
    Dijon Cedex, Cote dÝOr 21079, France
  • Research Site
    Besancon cedex, Doubs 25030, France
  • Research Site
    Nimes, Gard 30029, France
  • Research Site
    Bordeaux Cedex, Gironde 33076, France
  • Research Site
    Colmar cedex, Haut Rhin 68024, France
  • Research Site
    Toulouse cedex 1, Haute Garonne 31059, France
  • Research Site
    Limoges cedex, Haute Vienne 87042, France
  • Research Site
    Rennes cedex 09, Ille Et Vilaine 35033, France
  • Research Site
    Grenoble cedex 09, Isere 39043, France
  • Research Site
    Nantes cedex 1, Loire Atlantique 44093, France
  • Research Site
    Reims, Marne 51092, France
  • Research Site
    Lille Cedex, Nord 59020, France
  • Research Site
    Lille Cedex, Nord 59037, France
  • Research Site
    La Roche sur Yon, Vendee 85025, France
  • Research Site
    Poitiers cedex, Vienne 86021, France
  • Research Site
    Le Chesnay Cedex, Yvelines 78157, France
  • Research Site
    Nancy, 54035, France
  • Research Site
    Rouen Cedex, 76031, France
  • Research Site
    Budapest, 1076, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Pecs, 7623, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Veszprem, 8200, Hungary
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Bergamo, 24100, Italy
  • Research Site
    Bolzano, 39100, Italy
  • Research Site
    Castelfiorentino, 50051, Italy
  • Research Site
    Firenze, 50139, Italy
  • Research Site
    Genova, 16153, Italy
  • Research Site
    Messina, 98121, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Perugia, 06156, Italy
  • Research Site
    Pozzilli, 86077, Italy
  • Research Site
    Roma, 00135, Italy
  • Research Site
    Roma, 00189, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Torino, 10124, Italy
  • Research Site
    Almada, 2801-915, Portugal
  • Research Site
    Amadora, 2720-276, Portugal
  • Research Site
    Guimarães, 4835-044, Portugal
  • Research Site
    Lisboa, 1169-050, Portugal
  • Research Site
    Lisboa, 1649-035, Portugal
  • Research Site
    Loures, 2674-514, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Porto, 4200-319, Portugal
  • Research Site
    Setúbal, 2910-446, Portugal
  • Research Site
    Bratislava, 81369, Slovakia
  • Research Site
    Presov, 8081, Slovakia
  • Research Site
    Ljubljana, SI-1525, Slovenia
  • Research Site
    Maribor, 2000, Slovenia
  • Research Site
    Majadahonda, Madrid 28222, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Bilbao, 48013, Spain
  • Research Site
    Córdoba, 14011, Spain
  • Research Site
    El Palmar, 30120, Spain
  • Research Site
    Girona, 17007, Spain
  • Research Site
    Malaga, 29010, Spain
  • Research Site
    Sevilla, 41009, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Vigo, 36204, Spain
  • Research Site
    Zaragoza, 50009, Spain
08

References and documents

Publications

  • Berger T, Brochet B, Brambilla L, Giacomini PS, Montalban X, Vasco Salgado A, Su R, Bretagne A. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019 Dec 2;5(4):2055217319887191. doi: 10.1177/2055217319887191. eCollection 2019 Oct-Dec. Erratum In: Mult Scler J Exp Transl Clin. 2020 Apr 29;6(2):2055217320921146. doi: 10.1177/2055217320921146. PubMed 31832225 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Mar 2016, 29 months.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 29, 2013
StartActual
Oct 31, 2013
Primary completionActual
Mar 31, 2016
CompletionActual
Jan 9, 2020
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01930708
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Aug 29, 2013
Start date
Oct 31, 2013
Primary completion
Mar 31, 2016
Completion
Jan 9, 2020
Last update
Mar 19, 2020

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion